OUP user menu

Waldenström Macroglobulinemia
Development of Diagnostic Criteria and Identification of Prognostic Factors

Roger G. Owen MD, Sharon L. Barrans, Stephen J. Richards PhD, Sheila J.M. O’Connor MSc, J. Anthony Child MD, Liakat A. Parapia MD, Gareth J. Morgan PhD, Andrew S. Jack PhD
DOI: http://dx.doi.org/10.1309/4LCN-JMPG-5U71-UWQB 420-428 First published online: 1 September 2001

Abstract

To establish whether a combination of morphologic and immunophenotypic criteria could be developed to more precisely define Waldenström macroglobulinemia (WM) and prognostic factors, we retrospectively assessed the clinical and laboratory features of 111 cases of WM. Bone marrow infiltration by small lymphocytes was documented in each case; and diffuse, interstitial, nodular, and paratrabecular patterns of infiltration were documented in 58%, 32%, 6%, and 4% of cases, respectively. Ninety percent were characterized by a surface immunoglobulin–positive, CD19+CD20+CD5−CD10−CD23− immunophenotype.

The median overall survival from diagnosis was 60 months; univariate analysis revealed the following adverse prognostic factors: older than 60 years, performance status more than 1, platelet count less than 100 × 103/μL (<100 × 109/L), pancytopenia, and diffuse bone marrow infiltration. Associated median survival was 40, 38, 46, 28, and 59 months, respectively. Multivariate analysis revealed age, performance status, and platelet count as prognostically significant, but stratification of patients according to the International Prognostic Index had limited value.

We suggest defining WM by the following criteria: IgM monoclonal gammopathy; bone marrow infiltration by small lymphocytes, plasmacytoid cells, and plasma cells in a diffuse, interstitial, or nodular pattern; and a surface immunoglobulin–positive, CD19+CD20+CD5−CD10−CD23− immunophenotype.

Key Words:
  • Waldenström macroglobulinemia
  • Immunophenotype
  • Prognostic factors